TEKLA HEALTHCARE INVESTORS Form N-Q August 25, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0578
Expires: March 31, 2019
Estimated average burden
hours per response......10.5

FORM N-Q

QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number

811-04889

Tekla Healthcare Investors (Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA (Address of principal executive offices)

02110

(Zip code)

(Name and address of agent for service)

Registrant s telephone number, including area code: 617-772-8500

Date of fiscal year end: September 30

Date of reporting period: 6/30/17

Item 1. Schedule of Investments.

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

JUNE 30, 2017

(Unaudited)

| SHARES | | VALUE |
|---------------|--|-----------------|
| | CONVERTIBLE PREFERRED AND WARRANTS (a) (b) - 2.3% of Net | |
| | Assets | |
| | Biotechnology 0.7% | |
| 2,692,309 | BioClin Therapeutics, Inc. Series A (Restricted) (c) | \$ 1,750,001 |
| 1,039,811 | BioClin Therapeutics, Inc. Series B (Restricted) (c) | 777,779 |
| 3,696,765 | EBI Life Sciences, Inc. Series A (Restricted) (c) | 18,854 |
| 2,266,666 | GenomeDx Biosciences, Inc. Series C (Restricted) | 3,399,999 |
| 210,000 | Trillium Therapeutics, Inc. Series II (g) | 831,600 |
| | | 6,778,233 |
| | Health Care Equipment & Supplies (Restricted) 1.1% | |
| 3,364,723 | AlterG, Inc. Series C | 1,244,948 |
| 114,158 | CardioKinetix, Inc. Series C | 0 |
| 205,167 | CardioKinetix, Inc. Series D | 0 |
| 632,211 | CardioKinetix, Inc. Series E | 0 |
| 692,715 | CardioKinetix, Inc. Series F | 0 |
| N/A(d) | CardioKinetix, Inc. warrants (expiration 12/11/19) | 0 |
| N/A(d) | CardioKinetix, Inc. warrants (expiration 6/03/20) | 0 |
| 12,695 | CardioKinetix, Inc. warrants (expiration 8/15/24) | 0 |
| 951,000 | IlluminOss Medical, Inc. Series AA | 951,000 |
| 895,848 | IlluminOss Medical, Inc. Junior Preferred | 895,848 |
| 71,324 | IlluminOss Medical, Inc. warrants (expiration 3/31/27) | 0 |
| 4,720,000 | Tibion Corporation Series B | 0 |
| N/A(d) | Tibion Corporation warrants (expiration 07/12/17) | 0 |
| N/A(d) | Tibion Corporation warrants (expiration 10/30/17) | 0 |
| N/A(d) | Tibion Corporation warrants (expiration 11/28/17) | 0 |
| 3,750,143 | Veniti, Inc. Series A (c) | 4,503,172 |
| 1,881,048 | Veniti, Inc. Series B (c) | 2,352,815 |
| 1,031,378 | Veniti, Inc. Series C (c) | 1,526,027 |
| | | 11,473,810 |
| | Life Sciences Tools & Services (Restricted) 0.5% | |
| 3,669,024 | Labcyte, Inc. Series C | 4,622,970 |
| 160,767 | Labcyte, Inc. Series D | 221,858 |
| 122,220 | Labcyte, Inc. Series E | 196,774 |
| | | 5,041,602 |
| | Pharmaceuticals (Restricted) 0.0% | |
| 4,118,954 | Euthymics Biosciences, Inc. Series A (c) | 4,119 |
| | | 4,119 |
| | TOTAL CONVERTIBLE PREFERRED AND WARRANTS | |
| | (Cost \$34,234,085) | 23,297,764 |
| PDVI (OVD.) V | | |

PRINCIPAL AMOUNT

CONVERTIBLE AND NON-CONVERTIBLE NOTES - 0.0% of Net Assets

| | Convertible Notes (Restricted)(a) 0.0% | |
|-----------|---|-----|
| | Health Care Equipment & Supplies 0.0% | |
| \$ 74,456 | CardioKinetix, Inc. Promissory Note, 5.00%, due 7/31/17 (b) | 590 |

The accompanying notes are an integral part of this Schedule of Investments.

| PRINCIPAL AMOUNT | | | VALUE |
|---------------------|---------|---|---------------|
| | | Health Care Equipment & Supplies continued | |
| \$ | 285,294 | IlluminOss Medical, Inc. Promissory Note, 8.00%, due 3/31/18 | \$ 285,294 |
| | | | 285,884 |
| | | Pharmaceuticals 0.0% | |
| | 38,745 | Euthymics Biosciences, Inc. Promissory Note, 8.00%, due 5/31/18 (b) (c) | 19,372 |
| | | | 19,372 |
| | | TOTAL CONVERTIBLE NOTES | 305,256 |
| | | | |
| | | Non-Convertible Notes (Restricted)(a) (b) 0.0% | |
| | | | |
| | | Health Care Equipment & Supplies 0.0% | |
| | 342,899 | Tibion Corporation Non-Cvt. Promissory Note, 0.00%, due 12/31/18 (b) | 0 |
| | 40,596 | Tibion Corporation Non-Cvt. Promissory Note, 6.00%, due 04/17/18 (b) | 0 |
| | | TOTAL NON-CONVERTIBLE NOTES | 0 |
| | | TOTAL CONVERTIBLE AND NON-CONVERTIBLE NOTES | |
| | | (Cost \$782,467) | 305,256 |
| SHARES | | | |
| | | COMMON STOCKS AND WARRANTS - 90.8% of Net Assets | |
| | | | |
| | | Biotechnology 62.9% | |
| | 348,916 | Alexion Pharmaceuticals, Inc. (b) | 42,452,610 |
| | 80,940 | Alnylam Pharmaceuticals, Inc. (b) | 6,455,774 |
| | 358,742 | Amgen Inc. | 61,786,135 |
| | 305,244 | Biogen Inc. (b) | |